Skip to main content
    N

    Neuraxis, Inc. (NRXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $4.83
    -0.59 (-10.89%)

    Market Cap: $76.93M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Neuraxis, Inc. (NRXS) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Neuraxis (NRXS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Neuraxis reported EPS of -$0.52, below the -$0.21 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    25%(3/12)
    Avg Surprise
    -203.48%

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.12
    Range-$0.18 - -$0.06
    4 analysts
    Revenue Consensus
    $2.86M
    Range$2.16M - $3.57M
    4 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.19
    Range-$0.19 - -$0.19
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-216.7%
    60d ago-$0.16-18.8%
    30d ago-$0.16-18.8%
    7d ago-$0.16-18.8%
    Current-$0.19
    Revenue Consensus
    $2.70M
    Range$2.70M - $2.70M
    1 analysts

    Next Report

    NRXS has an expected report date of Mar 17, 2027.

    NRXS Earnings Call

    The latest NRXS earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 12 quarters below that had an estimate, NRXS beat 3 and missed 9. Revenue for the quarter ended Sep 30, 2026 was $2.03M, up 150.2% from $811414 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.52-$0.21-$0.21 - -$0.21-147.62%MissN/A10 up, 0 downNov 9, 2026$2.03M
    Jun 30, 2026-$0.19-$0.32-$0.50 - -$0.14+40.63%BeatN/A20 up, 1 downAug 11, 2026$1.93M
    Mar 31, 2026-$0.18-$0.24N/A+25.75%BeatN/A21 up, 0 downMay 12, 2026$1.61M
    Dec 31, 2025-$0.10-$0.21-$0.22 - -$0.17+52.38%BeatN/A20 up, 1 downMar 19, 2026$968127
    Sep 30, 2025-$0.24-$0.20-$0.24 - -$0.16-20.00%MissN/A20 up, 1 downNov 10, 2025$811414
    Jun 30, 2025-$0.22-$0.19-$0.20 - -$0.18-15.79%MissN/A21 up, 0 downAug 12, 2025$894086
    Mar 31, 2025-$0.33-$0.24-$0.24 - -$0.24-37.50%MissN/A10 up, 0 downMay 12, 2025$895655
    Dec 31, 2024-$0.21$0.04N/A-612.50%MissN/AN/AN/AMar 20, 2025$761165
    Sep 30, 2024-$0.25N/AN/AN/AN/AN/AN/A0 up, 0 downNov 12, 2024$666625
    Jun 30, 2024-$0.42-$0.05N/A-743.20%MissN/AN/A0 up, 0 downAug 9, 2024$611500
    Mar 31, 2024-$0.32-$0.10N/A-220.00%MissN/AN/A0 up, 0 downApr 9, 2024$646635
    Dec 31, 2023-$0.25-$0.15N/A-69.80%MissN/AN/A0 up, 0 downFeb 28, 2024$531458
    Sep 30, 2023-$1.35-$0.17-$0.17 - -$0.17-694.12%MissN/A10 up, 0 downNov 20, 2023$477460
    Jun 30, 2023-$1.21N/AN/AN/AN/AN/AN/AN/AAug 11, 2023$646021
    Mar 31, 2023-$0.38N/AN/AN/AN/AN/AN/AN/AMay 31, 2023$805110
    Last 15 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.89, after -$1.20 the year before. It was -$3.19 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.89N/A
    Dec 31, 2024-$1.20N/A
    Dec 31, 2023-$3.19N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,900 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20265,8585
    2025Q4Dec 31, 20257,5817
    2025Q3Sep 30, 20255,4825
    2025Q2Jun 30, 20255,5835
    2025Q1Mar 31, 20254,3794
    2024Q4Dec 31, 20244,8844
    2024Q3Sep 30, 20246,0415
    2024Q2Jun 30, 20244,7945

    2026Q1 Earnings Call

    Opening remarks

    Behnam Shamsian Investor Relations Thank you, and good morning, everyone. Thank you for joining us for NeurAxis' First Quarter 26 Financial Results and Corporate Update Conference Call. Joining us on today's call is Brian Carrico, CEO of NeurAxis, and Timothy Henrichs, CFO of NeurAxis. At the conclusion of today's prepared remarks, we will open the call to questions. Please follow the operator's instructions to ask questions. Today's event is being recorded and will be available for replay through the webcast information provided in the press release. Finally, I would also like to call your attention to the customary safe harbor disclosures regarding forward-looking information. The conference call today will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations, and future potential financial and operational results of NeurAxis. Although management believes these statements are reasonable based on estimates, assumptions, and projections as of today, these statements are not guarantees of future performance. Time-sensitive information may no longer be accurate at the time of any telephonic or webcast replay. Actual results may differ materially as a result of risks, uncertainties, and other factors, including, but not limited to, the factors set forth in the company's filings with the SEC. NeurAxis undertakes no obligation to update or revise any of these forward-looking statements. With that said, I would like to turn the event over to Brian Carrico.

    Operator Operator Chief Executive Officer of NeurAxis. Brian, please proceed.

    Brian Carrico Chief Executive Officer Thank you, Ben, and good morning to everyone joining us. Good to talk to everyone again. Quarter 26 was an important quarter for NeurAxis. I talked a little bit about this on the last earnings call 6 or 7 weeks ago. It was our first full quarter of operating with the Category 1 CPT code for PENFS, and it gave us the clearest view to date of what drives adoption, what continues to limit broader utilization, and where we need to focus our resources. I will structure my remarks today around six key areas. Number one, revenue and first quarter highlights; number two, insurance coverage status and payer progress; number three, key performance indicators or KPIs; number four, commercialization including our current structure, new hires and upcoming changes; number five, the VA opportunity; and number six, a summary of our focused next steps. Following my remarks, Timothy Robert Henrichs, our CFO, will review our financial results for the first quarter of 2026. For the first quarter 26, revenue was $1.6 million, compared with $896 thousand in Q1 2025, representing 80% year-over-year revenue growth. The quarter modestly exceeded our expectations, but the more important point is what we learned from the quarter.

    Frequently Asked Questions About NRXS

    When is Neuraxis's next earnings date?

    Neuraxis's next earnings report is expected for Mar 17, 2027.

    Did NRXS beat earnings estimates last quarter?

    No. Neuraxis reported EPS of -$0.52 for the quarter ended Sep 30, 2026, below the -$0.21 estimate by 147.62%.

    What EPS do analysts expect from NRXS next quarter?

    The consensus EPS estimate for Neuraxis for the quarter ending Dec 31, 2026 is -$0.12 from 4 analysts, with estimates from -$0.18 to -$0.06.

    How often does NRXS beat earnings estimates?

    Neuraxis beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -89.33%.